Collegium Pharmaceutical (NASDAQ:COLL) had its price objective increased by Needham & Company LLC from $25.00 to $28.00 in a research report issued on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential upside of 62.70% from the stock’s previous close. The analysts noted that the move was a valuation call.
Other equities analysts have also recently issued research reports about the stock. Jefferies Group increased their price objective on shares of Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research note on Tuesday. Piper Jaffray Companies set a $19.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, November 29th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Monday, November 13th. Two analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.50.
Collegium Pharmaceutical (NASDAQ COLL) opened at $17.21 on Tuesday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. During the same quarter in the prior year, the business earned ($1.13) EPS. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. analysts expect that Collegium Pharmaceutical will post -2.56 earnings per share for the current year.
In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total transaction of $68,493.00. Following the sale, the chief technology officer now owns 28,513 shares in the company, valued at approximately $484,721. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alison B. Fleming sold 4,601 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the sale, the insider now owns 28,513 shares in the company, valued at approximately $491,849.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,630 shares of company stock worth $924,360. 25.76% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares in the last quarter. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $125,000. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares in the last quarter. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares in the last quarter. 79.98% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/07/collegium-pharmaceutical-coll-pt-raised-to-28-00-at-needham-company-llc.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.